BMC Cancer (2015) 12(15):272.10.1186/s12885-015-1267-0 38 FilopantiMBarbieriAMAngioniARColaoAGascoVGrottoliSet alDopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas
Proc Am Assoc Cancer Res:(#3326), 2007
However, these findings are based on the inhibition of administered GIP, and, therefore, they do not describe the clinical effect of GIP receptor antagonism and inhibition of endogenous GIP in adipose tissue
During committee discussions, some lawmakers raised concerns about both the cost of the drugs and the potential side effects, which they say could lead to additional medical expenses paid for by taxpayers
If you have questions about your current dose or aren't seeing the results you expected, your care team is available to help
Henriques P, Bicker J, Carona A, Miranda M, Vitorino C et al (2023) Amorphous nasal powder advanced performance: in vitro/ex vivo studies and correlation with in vivo pharmacokinetics